FCM
BCLI

Fourpath Capital Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Fourpath Capital Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-69
Closed -$238 – 283
2024
Q3 		$238 Buy
+69
New +$326 ﹤0.01% 753

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fourpath Capital Management's BCLI Position: Q4 2024 in Review

Fourpath Capital Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2024, closing a stake of 69 shares — an estimated $238 sold.

Fourpath Capital Management first reported a position in BCLI in Q3 2024 and held it in 1 quarter. The position peaked at $238 in Q3 2024. 34 funds tracked by Wall St. Rank hold BCLI as of Q4 2024.

  • Fourpath Capital Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2024 after selling out during the quarter.
  • Fourpath Capital Management sold 69 BRAINSTORM CELL THERAPUTC shares in Q4 2024, an estimated $238.
  • Fourpath Capital Management first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2024 and held it in 1 quarter.
  • Fourpath Capital Management's BRAINSTORM CELL THERAPUTC position peaked at $238 in Q3 2024.
  • 34 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2024.

Based on Fourpath Capital Management's 13F filing for Q4 2024, filed 24 Jan 2025.